DiaSorin and QIAGEN N.V. announce the launch in the CE market of the LIAISON QuantiFERON-TB Gold Plus as an aid to detect latent tuberculosis infection (LTBI) on LIAISON analyzer systems.
The new test was developed in a partnership between DiaSorin and QIAGEN to help address accelerating conversion of the global LTBI testing market to the modern blood-based QuantiFERON technology.
The launch of the new LIAISON QuantiFERON-TB Gold Plus is meant to provide laboratories with the first and only available CLIA detecting solution in the European market on the LIAISON family platforms, simplifying and speeding-up the second step of the TB testing process, as a consequence of the incremental strong demand of the TB testing volumes worldwide.
For more information: http://www.diasorin.com/sites/default/files/allegati_pressrel/pr_diasorin_liaison_qft-plus.pdf